ESMO 2021: Belzutifan (MK-6482) plus cabozantinib for advanced clear cell RCC
Kidney cancers frequently have mutations in the von Hippel-Lindau (VHL) [...]
FDA approves belzutifan for VHL kidney cancer
The FDA has approved a new drug called belzutifan for [...]
FDA grants priority review for HIF-2α inhibitor belzutifan (MK-6482)
The US Food and Drug Administration (FDA) has granted priority [...]
Updated results from a trial with belzutifan for people with advanced kidney cancer
Kidney cancers frequently have mutations in the von Hippel-Lindau (VHL) gene, [...]
ASCO GU 2021: Combination of HIF-2α inhibitor and cabozantinib is active in previously treated advanced kidney cancer
In a small phase 2 study presented at the virtual [...]
Future for VHL kidney cancer is bright
Von Hippel-Lindau (VHL) disease–associated renal cell carcinoma (RCC) has always [...]
